SonoThera™ to Present Late Breakthrough Data at ISTH 2024 on Development of Nonviral Hemophilia A Gene Therapy Treatment
- Data focuses on an engineered Factor Eight (FVIII) protein for enhanced gene expression and secretion to achieve normal levels of FVIII in plasma using SonoThera’s novel, ultrasound-guided gene delivery platform.
- SonoThera’s platform is being developed to non-invasively deliver nucleic acid payloads of diverse formats and sizes to targeted organs and tissues.
South San Francisco, CA, June 23, 2024 – SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, will present late breakthrough data at the 32nd Congress of the International Society of Thrombosis and Haemostasis (ISTH) taking place in Bangkok, Thailand, June 22-26, 2024.
The oral presentation features SonoThera’s engineered Factor Eight (FVIII) protein for enhanced gene expression and secretion that achieves normal levels of FVIII in plasma when administered using its proprietary ultrasound-guided nonviral gene delivery platform. SonoThera’s ultrasound gene delivery platform is a targeted approach that provides durable gene expression with the ability to redose and to dose titrate.
“Current gene delivery methods for treating Hemophilia A have several limitations,” said Kenneth Greenberg, PhD, CEO of SonoThera. “These include lack of durable expression, redosing capability, immunogenicity to viral vectors, and high product cost. We believe there is a need for an alternative, nonviral gene therapy for Hemophilia A and we look forward to presenting our latest data in support of this approach at ISTH.”
June 23rd Oral Presentation Details:
Title: Engineering FVIII protein for enhancing expression and secretion profile to achieve normal level of FVIII in plasma utilizing noninvasive transcutaneous ultrasound mediated gene delivery.
Presenter: Ivan Krivega, PhD, Senior Director, Gene Therapy, SonoThera
Session Date/Time: Sunday, June 23rd, 9:45-10:00 ICT (9:30-10:45), Plenary Hall
Session Number: LB 01.2
About SonoThera™
Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera, Inc. is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing therapies using its proprietary ultrasound-guided, nonviral gene therapy platform that is designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. SonoThera is headquartered in South San Francisco, California. Visit www.sonothera.com to learn more.
Investor Inquiries:
investors@sonothera.com
Media Inquiries:
Mog & Springer Communications on behalf of SonoThera, Inc.
Elizabeth Harness, Principal, P: +1 585-435-7379, elizabeth.harness@mogandspringer.com